John Lechleiter, Eli Lilly CEO, breaks down the company's quarterly results which reported EPS of $0.88 (adj.) on revenues of $5.19 billion.
John Lechleiter, Eli Lilly chairman & CEO, talks about Eli Lilly expanding global health care access and expanding its pipeline of new drugs.
The Fast Money Halftime Report traders discuss where Wall Street stands on specific companies.
The "Fast Money Halftime Report" traders; Stephanie Link, TIAA Global Asset Management; and CNBC's Jim Cramer discuss the trade on Eli Lilly following Goldman Sachs' upgrade of the stock to buy from neutral.